Spotlighting the Translational Profile of KIVU 107 to Strive for Kinder & Gentler ADC Therapies With Enhanced Therapeutic Index - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Spotlighting the Translational Profile of KIVU 107 to Strive for Kinder & Gentler ADC Therapies With Enhanced Therapeutic Index

11:00 am - Tuesday 13th October 2026

Laying out rationale for pursuing less toxic ADC development to enable higher dosing and expand ADC therapeutic index
Breaking down late-stage preclinical data of KIVU-107 in solid tumors to emphasize clinical opportunity and differentiation strategy
Unveiling the emerging clinical profile of KIVU-107 to investigate how well preclinical data translates to patient responses and lay out ongoing clinical development strategy

Speakers:

Mohit Trikha

Mohit Trikha

Chief Executive Officer

Kivu Biosciences